JP2023544327A5 - - Google Patents
Info
- Publication number
- JP2023544327A5 JP2023544327A5 JP2023519794A JP2023519794A JP2023544327A5 JP 2023544327 A5 JP2023544327 A5 JP 2023544327A5 JP 2023519794 A JP2023519794 A JP 2023519794A JP 2023519794 A JP2023519794 A JP 2023519794A JP 2023544327 A5 JP2023544327 A5 JP 2023544327A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- amount
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086353P | 2020-10-01 | 2020-10-01 | |
| US63/086,353 | 2020-10-01 | ||
| PCT/US2021/053141 WO2022072811A1 (en) | 2020-10-01 | 2021-10-01 | Pharmaceutical formulations for treating diseases mediated by kdm1a |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544327A JP2023544327A (ja) | 2023-10-23 |
| JP2023544327A5 true JP2023544327A5 (cg-RX-API-DMAC10.html) | 2024-10-09 |
| JP7848195B2 JP7848195B2 (ja) | 2026-04-20 |
Family
ID=80951023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519794A Active JP7848195B2 (ja) | 2020-10-01 | 2021-10-01 | Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤 |
Country Status (10)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| US20250275969A1 (en) | 2022-05-09 | 2025-09-04 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962488A (en) * | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
| US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
| CN104784180A (zh) | 2008-07-28 | 2015-07-22 | 武田药品工业株式会社 | 药物组合物 |
| JP4816828B2 (ja) * | 2009-03-30 | 2011-11-16 | アステラス製薬株式会社 | ソリフェナシン非晶質体を含有した固形医薬組成物 |
| CA2848493A1 (en) * | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
| WO2015170237A1 (en) * | 2014-05-05 | 2015-11-12 | Torrent Pharmaceuticals Limited | Stable solifenacin composition |
| JP6727216B2 (ja) * | 2015-02-12 | 2020-07-22 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| US20190070172A1 (en) * | 2015-11-05 | 2019-03-07 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| CN111194306B (zh) * | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| MX2022007113A (es) * | 2019-12-09 | 2022-07-11 | Imago Biosciences Inc | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. |
-
2021
- 2021-10-01 AU AU2021351536A patent/AU2021351536A1/en active Pending
- 2021-10-01 KR KR1020237014383A patent/KR20230079151A/ko active Pending
- 2021-10-01 CA CA3193661A patent/CA3193661A1/en active Pending
- 2021-10-01 CN CN202180068111.4A patent/CN116367831A/zh active Pending
- 2021-10-01 EP EP21876583.2A patent/EP4221704B1/en active Active
- 2021-10-01 WO PCT/US2021/053141 patent/WO2022072811A1/en not_active Ceased
- 2021-10-01 JP JP2023519794A patent/JP7848195B2/ja active Active
- 2021-10-01 MX MX2023003783A patent/MX2023003783A/es unknown
- 2021-10-01 BR BR112023005987A patent/BR112023005987A2/pt unknown
-
2023
- 2023-03-23 US US18/188,578 patent/US20230293495A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5752107B2 (ja) | 薬物高含量錠剤 | |
| US11911509B2 (en) | Pharmaceutical composition comprising Lenvatinib mesylate | |
| CN110719782A (zh) | 包含小分子egfr抑制剂的药物组合物及其制备方法 | |
| JP6301934B2 (ja) | チカグレロルを含む固形経口医薬製剤 | |
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| WO2020004630A1 (ja) | 難溶性の塩基性薬剤を含有する医薬組成物 | |
| EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
| CA2623018A1 (en) | Pharmaceutical compositions of telmisartan | |
| JP2012513978A (ja) | オルメサルタン製剤処方 | |
| US20150328172A1 (en) | Tablet Composition Comprising Cinacalcet Hydrochloride | |
| JP7226697B2 (ja) | ブロナンセリン含有錠剤 | |
| JP2023551712A5 (cg-RX-API-DMAC10.html) | ||
| US20120035177A1 (en) | Tablet formulation for p38 inhibitor and method | |
| JP2023183393A (ja) | グアンファシン塩酸塩含有製剤 | |
| US20110033533A1 (en) | Galenical formulations of organic compounds | |
| EP4268806A1 (en) | A tablet comprising sacubitril and valsartan processed with dry granulation | |
| JP7511596B2 (ja) | リバーロキサバン含有錠剤 | |
| WO2023211412A1 (en) | A tablet comprising sacubitril and valsartan processed with dry granulation | |
| JP2009502957A (ja) | 機械的特性の向上した徐放性錠剤配合物 | |
| JP5525453B2 (ja) | 医薬組成物 | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| JP7423297B2 (ja) | 口腔内崩壊錠およびその製造方法 | |
| WO2007142546A2 (en) | Sustained release coated tablet with precisely regulated release profile | |
| JP2024090218A (ja) | 崩壊遅延を改善したゾニサミド含有口腔内速崩壊錠 | |
| EP4731191A1 (en) | Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide |